XOMA 358

Drug Profile

XOMA 358

Alternative Names: Human allosteric modulating monoclonal antibody - XOMA; X 358; XOMA 247; XOMA358; XPA.15.247

Latest Information Update: 14 Feb 2017

Price : $50

At a glance

  • Originator XOMA
  • Class Antihyperglycaemics; Monoclonal antibodies
  • Mechanism of Action Insulin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperinsulinaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperinsulinaemia; Hypoglycaemia

Most Recent Events

  • 01 Jan 2017 XOMA completes a phase II trial in Hyperinsulinaemia in United Kingdom and USA (NCT02604485)
  • 15 Sep 2016 Initial pharmacodynamics data from phase II trials in Hyperinsulinaemia (In adolescents, In adults) and Hypoglycaemia released by XOMA
  • 15 Sep 2016 XOMA plans a phase IIb trial in Hypoglycaemia in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top